SIMPL’HIV Wk 144 Results: Dolutegravir + Emtricitabine vs Standard Combination ART for Maintenance of Virologic Suppression

July 29-August 2, 2022; Montreal, Quebec
Switching from standard combination ART to DTG plus FTC was noninferior to continuing standard combination ART in virologically suppressed adults through Week 144 in this randomized clinical trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 222 KB
Released: August 2, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Related Content

Dr William R. Short: key considerations for the use of long-acting cabotegravir and rilpivirine in pregnancy, from Clinical Care Options (CCO)

William R. Short, MD, MPH, AAHIVS Released: September 28, 2022

Dr William R. Short: key considerations for deciding whether to continue bictegravir in pregnancy, from Clinical Care Options (CCO)

William R. Short, MD, MPH, AAHIVS Released: September 28, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure

Joseph J. Eron, Jr., MD Jeffrey Kwong, DNP, MPH, FAANP, FAAN Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP David A. Wohl, MD Released: September 23, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, and comorbidities

Jeffrey Kwong, DNP, MPH, FAANP, FAAN Released: September 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings